BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

Atlanta Dermatology, Vein & Reseach Center, LLC

Atlanta Dermatology, Vein & Reseach Center, LLC is a state-of-the-art medical office owned by Dr. Tiffani Hamilton. Dr. Hamilton's medical training began at the University of Utah School of Medicine. Following medical school, Dr. Hamilton remained at the University of Utah for an internship in Internal Medicine. She then completed her Dermatology Residency at Dartmouth-Hitchcock Medical Center where she was the Chief Resident from 1997 to 1998.


Contact Details:
4165 Old Milton Parkway, Suite 150 W
Alpharetta
Georgia
30005
United States of America
Tel:770.360.8881
Fax:770.255.2533
Email:
WWW:

www.dermandvein.com/




Loading...

Recent Publications by Atlanta Dermatology, Vein & Reseach Center, LLC:

Multiple pebbly blue papules in a segmental distribution.
The incidence of the post-thrombotic syndrome (PTS) is increasing along...
30th August, 2008
Department of Dermatology, Changi General Hospital, Singapore. Pediatr Dermatol. 2008 May-Jun;25(3):381-2.
DOI Direct Link
Endovenous therapies of lower extremity varicosities are at least as effective as surgical stripping or foam sclerotherapy: Meta-analysis and meta-regression of case series and randomized clinical trials.
BACKGROUND: Minimally invasive techniques such as endovenous laser...
12th August, 2008
Departments of Dermatology, Rotterdam, the Netherlands. J Vasc Surg. 2008 Aug 8.
DOI Direct Link
Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165.
Vascular endothelial growth factor (VEGF) is a pleiotropic factor that...
8th August, 2008
Department of Dermatology, Faculty of Medicine, Shimane University, Growth Factors. 2008 Jun;26(3):125-31.
DOI Direct Link
Anti-endothelial cell IgG from patients with chronic arsenic poisoning induces endothelial proliferation and VEGF-dependent angiogenesis.
An endemic peripheral vascular disorder due to chronic arsenic poisoning,...
2nd August, 2008
Department of Dermatology, Kaohsiung Medical University Hospital and Microvasc Res. 2008 Jul 11.
DOI Direct Link
Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial.
BACKGROUND: Psoriasis is a chronic autoimmune disease characterized by...
19th July, 2008
Atlanta Dermatology, Vein & Research Center, Atlanta, Georgia, USA. Drug Saf. 2008;31(8):715-26.

View more Atlanta Dermatology, Vein & Reseach Center, LLC research publications.

BioNews Results for Atlanta Dermatology, Vein & Reseach Center, LLC:

Longer-term safety profile of efalizumab in psoriasis confirmed
MedWire News:  Jul 25 2008 3:57PM Matching: atlanta dermatology vein

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 149 times since April 2007, the link to the organisation's website has been followed 35 times

Recent Search Terms used to find this page: atlanta dermatology.vein | atlanta dermatology and vein | pentazocine | .

Search for more companies in Alpharetta

Search for more companies in Georgia



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Atlanta Dermatology, Vein & Reseach Center, LLC
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.